AB0284 Long term safety of iv golimumab and comparisons with sc golimumab in rheumatologic conditions: results from the 120-day safety report of go-further trial

R. Westhovens; C. O. Bingham; M. Weinblatt; R. Fleischmann; E. Keystone; E. C. Hsia; B. Hsu; L. Kim; S. Mudivarthy; M. Mack; N. Goldstein; J. Braun; A. Kavanaugh; A. Mendelsohn; J. Kay

doi:10.1136/annrheumdis-2013-eular.2606

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

Abstracts accepted for publication

Rheumatoid arthritis - anti-TNF therapy

AB0284 Long term safety of iv golimumab and comparisons with sc golimumab in rheumatologic conditions: results from the 120-day safety report of go-further trial

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password